**Name of journal:** **World Journal of Gastroenterology**

**ESPS Manuscript NO: 18092**

**Manuscript type: Topic Highlights**

**2015 Advances in Gastric Cancer**

**New blood markers detection technology: A leap in the diagnosis of gastric cancer**

Beeharry MK *et al*. New blood markers for gastric cancer

Maneesh K Beeharry**,** Wen-tao Liu, Min Yan, Zheng-gang Zhu

**Maneesh K Beeharry, Wen-tao Liu, Min Yan, Zheng-gang Zhu,** Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai 200025, China

**Author contributions:** Beeharry MK performed the literature research, data analysis and wrote the manuscript; Liu WT contributed to the literature research and provided a critical revision of the manuscript; Yan M and Zhu ZG supervised the study and provided a critical revision of the manuscript prior to submission.

**supported by** National Natural Science Foundation of China, No. 30872477 and No. 30901729**.**

**Conflict-of-interest statement:** The authors of the manuscript hereby declare no conflict of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Wen-tao Liu, MD, PhD**, Key Laboratory of Shanghai Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University, 197 Ruijin Road II, Shanghai 200025, China. wt\_mygod@163.com

**Telephone:** +86-21-64370045

**fax:** +86-21-64314781

**Received:** April 5, 2015

**Peer-review started:** April 7, 2015

**First decision:** September 9, 2015

**Revised:** September 28, 2015

**Accepted:** November 24, 2015

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC) is still one of malignant tumors with high morbidity and mortality in the world, with a 5-year survival rate of less than 30%. GC is often either asymptomatic or causing only nonspecific symptoms in its early stages, whereby when the symptoms manifest, the cancer has usually reached an advanced stage, which is one of the main causes of its relatively poor prognosis. Hence, the main focus of GC research has been on discovering new tools and technology to predict, screen and diagnose GC at an early stage which would prompt for early treatment. With the tremendous advances in the OMICS technology, serum proteomics has been in the limelight of cancer research over the last few decades and has steered the development of several methods helping to understand the mechanisms underlying gastric carcinogenesis, resulting in the identification of a large number of molecular targets such as circulating tumor cells (CTCs), cell free DNA (cfDNA) and cell tumor DNA (ctDNA) and their sub-molecular components such as miRNA, that show great promise as GC biomarkers. In this review, we are underlying the recent breakthroughs about new blood markers technology for GC while scrutinizing the potential clinical use of CTCs, cfDNA, ctDNA and the role of the methylation of their sub-molecular components in the pathogenesis, diagnosis and management of GC.

**Key words:** Gastric cancer; Circulating tumor cells; Circulating tumor DNA; Proteomics; Biomarkers; Methylation

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastric cancer (GC)’s poor prognosis has partly been a result of its late diagnosis due to its asymptomatic and nonspecific symptoms in its early stages. Tremendous advances in the OMICS technology have allowed the development of several methods helping to understand the mechanisms underlying gastric carcinogenesis, resulting in the identification of a large number of molecular targets such as circulating tumor cells, cell free DNA, cell tumor DNA and their sub-molecular components such as miRNA that show great promise as GC biomarkers. In this review, we are underlying the recent breakthroughs about new blood markers technology for GC while scrutinizing their potential clinical use in the pathogenesis, diagnosis and management of GC.

Beeharry MK**,** Liu WT, Yan M, Zhu ZG. New blood markers detection technology: A leap in the diagnosis of gastric cancer. *World J Gastroenterol* 2015; In press

**Introduction**

Gastric cancer (GC), is still one of the world’s malignant tumors with high morbidity and mortality with 1 new million cases and about 800000 cases of death per annum. According to the literature of GC, the 5-year survival rate is less than 30%[1]. In recent years, the advances made in the GC detection methods and treatment have definitely influenced the clinical outcome of patients but still, due to late diagnosis, the main clinical issue that requires attention still pertains to the high prevalence of metastasis and recurrence. In the quest for tools for early diagnosis, scientists and physicians have entailed on long research about blood tumor markers which could detect GC, prompting for early intervention.

Clinically, the detection of the physiological indicators or parameters of the serum has been always an auxiliary for the diagnosis of cancer[2]. Over the years, there have been major breakthroughs in the field of serum proteomics where more attention has been paid quantitative or qualitative changes undergone by some important regulatory proteins secreted into the serum under many physiological and pathological conditions[3]. However, the positive rate of the currently clinically popular gastrointestinal tumor biomarkers CEA, CA19-9 and CA72-4 has been found to be lower than 40% in GC patients and lower than 20% in early GC patients, hereby making them insufficient for the diagnostic screening[4,5]. Hence, due to the lack of the specificity or sensitivity of such markers, researchers have been on the constant urge to discover the most convenient tool to diagnose GC.

Over the last few decades, there have been major breakthroughs in the field of serum proteomics where in addition to the conservative methods of cancer detection, there was a new leap in the blood markers detection technology. In addition to the continued investigation about novel and unbiased GC serum biomarkers by different and innovative proteomics techniques, new concepts such as circulating tumor cells (CTC) and circulating tumor DNA (ctDNA) have been introduced[6-8]. Previous studies state that during the early stages of tumor formation, tumor cells and tumor DNA are released in the peripheral blood. The tumor cells and related DNA shed off in the circulatory system during tumor evolution have been followed closely over the last few years and it was found out that the qualitative and quantitative analysis of CTC and ctDNA was related to the diagnosis, evolution, follow-up and prognosis of tumors. As an alternative to primary tumor “liquid biopsy specimen”[7,9,10], CTC has already been approved by the FDA as a prognostic evaluation factor for metastatic breast, prostate and colorectal cancers[11]. Hence, this new leap in the blood markers detection technology has provided a new platform for the early detection and diagnosis for GC while providing a more efficient tool for the evaluation of treatment efficacy and prediction of recurrence and metastasis.

***Serum proteomics***

In 1994, the concept of the proteome was brought to light by Wilkins and Williams from Macquarie University and after that, the proteomics and related techniques underwent rapid development, allowing the large-scale screening of tumor biomarkers. Serum proteomics can be used to perform differential analysis of serum protein between cancer patients and healthy controls and in so doing, differential specific and unbiased proteins could hence be adopted as tumor biomarkers for the early diagnosis of cancer. So far, several serum tumor biomarkers have been identified for GC but due to their poor specificity and sensitivity, they have proven to be insufficient for the reliable diagnosis of GC. Thus, there is the urging need to find more reliable serum tumor biomarkers for earlier and reliable diagnosis of GC. In a study made byour research team, the role of new modern and advanced proteomic techniques, such as Surface-enhanced Laser Desorption Ionization (SELDI) and High Performance Liquid Chromatography (HPLC), in the quest for new GC biomarkers was assessed: numerous novel serum tumor biomarkers such as Amyloidrelated Serum Protein (SAA), plasminogen and C9c have been discovered through serological proteomics strategies[3,12] and these techniques have been well adopted throughout the globe in the fight against GC.

Proteomic-based techniques such as 2-DE (two-dimensional electrophoresis), iTRAQ (isobaric tags for relative and absolute quantitation), ICAT (isotope-coded affinity tag), protein chip array and liquid chromatography, have been used to identify and quantify proteins that can be used as biomarkers in bodily fluids and tissues in GC[3,12,13]. To date, the most common fluid biomarkers available for GC include CEA, CA 19-9, CA 72-4, CYFRA 21-1, TPA, TPS, E-cadherin, pepsinogen, cytokines and the β-subunit of HCG.

As reported, the majority of tumor biomarkers in GC diagnosis are glycoproteins[14], with the most common being mucin-5AC (*MUC5AC*), IgG, mucin-1 (*MUC1)*, *IGHM, LRG1*, haptoglobin (HP), albumin (*ALB*), TF, kininogen-1 (*KNG1*), alpha-1-acid glycoprotein (*AGP*), ceruloplasmin (*CP*), *A1BG*, vitamin D binding protein (*GC*), alpha-1-antitrypsin (*SERPINA1*), antithrombin (*SERPINC1*), angiotensin (*AGT*), *CFB*, serpin peptidase inhibitor, Clade A (*SERPINA3*), alpha-2-HS-glycoprotein (*AHSG*), Zn-alpha-2-glycoprotein (*AZGP1*), *CLU, ITIH2*, complement factor H (*CFH)*, interalpha-trypsin inhibitor *HCRP, SERPING1* and C4A variant protein (*C4A)*[15-17]. These glycoproteins have been discovered and highly investigated over the last few decades but still, more research has to be done to evaluate their clinical value, their specificity and accuracy in predicting or evaluating GC.

Recently, Li *et al*[18] studied two multidrug-resistant cell lines and their parental drug-sensitive GC cell line to characterize the multiple drug resistance (MDR)-related cell surface glycoproteome: 56 cell membrane glycoproteins were successfully identified, 11 of which (*Mesothelin, EGFR, Integrin alpha-3, CD59, Folate receptor alpha, Peptidyl-prolyl cis-trans isomerase FKBP9, Laminin subunit alpha-5, Dihydropyridine receptor alpha 2, Multidrug resistance protein 1, Prostaglandin F2 receptor negative regulator and Golgi apparatus protein 1*) were found to be differentially expressed with the same trend in both the drug-resistant and sensitive cell lines. This report was the first concerning the relationship between glycoprotein alterations and MDR in gastric tumors and was also helpful for better interpreting the sophisticated mechanisms of MDR in GC, which, of course, still require further investigation and verification.

Given the current multiplicity of proteomic studies in GC, due to the vast amounts of data generated, it is important to maintain an up-to-date and searchable index of the lists of biomarkers obtained and evaluated from different research works. It is eventually essential that future research not only focus on identifying the disease-associated alterations in the proteins but also on determining the cellular functions of the proteins identified as well as the mechanistic networks in which they participate. The biomarkers identified experimentally should serve as entry points for investigating the mechanisms of carcinogenesis and tumor progression.

With the developments in proteomics and mass spectrometry, a large number of new methods and technology has been used in the serum proteomics research for GC. Since tumor markers lack specificity, particularly in the early stages of cancer, there have been a lot of research laying more emphasis on the different combinations of peptides or glucoside secreted into blood rather than protein markers and then, GC diagnosis models have been established based on the statistical information. The SELDI method has been one of the most popular proteomics technologies over the last few years and despite its high diagnostic rate, this method has poor repeatability and reliability, hereby hindering its reliability and clinical application. Hence, this research group has used the magnetic beads combined with mass spectrometry technology for the diagnosis of GC since the repeatability and clinical value of this method are relatively higher, mostly due to high capture efficiency of the magnetic beads for the specific proteins and peptides, hence improving the diagnostic accuracy and specificity for GC[3]. Our research team used serum proteomics to analyze serum samples from 20 GC patients including pTNM stages I to IV, where serum proteins were separated by 2-DE and identified by MALDI–TOF/TOF–MS; the results showed 3 proteins, complement C4-B precursor, complement factor I (CFI) precursor and haptoglobin precursor in the GC patients were significantly different between the normal control group while western blot showed that the detection of CFI precursor was under-expressed in GC with declining expression while advancing from pTNM stage I to IV GC and this implied that 2-DE-based serum proteome analysis could not only be useful in the screening of serum biomarkers for GC, but the CFI precursor could also help in the diagnosis and indicate disease progression in GC[12].

Li *et al*[19] used proteomic analysis of serum samples for identifying gastric precancerous lesions and GC by studying the serum samples from 25 patients with gastric precancerous lesions (chronic atrophic gastritis with mild to moderate dysplasia), 25 GC patients and 25 healthy controls using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS): the spectral peaks for the peptides with mass-to-charge (m/z) values of 1741 and 4210 were the most significantly different among the three groups and the sensitivity of this diagnostic model for detecting healthy controls, patients with gastric precancerous lesions and patients with GC was found to be 80.0% (12/15), 66.7% (10/15) and 66.7% (10/15) respectively, while the specificity was 66.7% (20/30), 73.3% (22/30) and 73.3% (22/30), respectively. Lu *et al*[20] analyzed 125 serum samples from GC patients and normal healthy control subjects using surface-enhanced laser desorption/ionization technology and the results of the surface-enhanced laser desorption/ionization model were compared with the biomarkers CEA and CA199 in a subset of samples using a micro-particle enzyme immunoassay: the results showed that 5 distinct protein peaks at 2046, 3179, 1817, 1725 and 1929 m/z were automatically chosen as components of the best biomarker pattern for diagnosis of GC. Lu *et al* also identified a single protein peak at 4665 m/z, which could distinguish between stage I/II and stage III/IV GC with a specificity and sensitivity of 91.6% (11/12) and 95.4% (21/22), respectively. When this biomarker was validated in the second set of samples, the specificity and sensitivity were 91.7% (11/12) and 86.3% (19/22), respectively, suggesting that the serum surface-enhanced laser desorption/ionization protein profiling could distinguish the GC patients and in particular stage I/II patients, from normal subjects with relatively high sensitivity and specificity. Even though more clinical evidence with a bigger data pool is required, but Surface-enhanced Laser Desorption/ionization-Time-of-flight-Mass Spectrometry proves to be new potential as a screening tool for GC.

***Circulating tumor cells***

Circulating tumor cells (CTCs) are cells shed into the vasculature from a primary tumor and circulate in the bloodstream[21]. CTCs were observed for the first time in 1869 by Thomas Ashworth[11] who postulated that “cells identical with those of the cancer itself being seen in the blood might tend to throw some light upon the mechanisms behind cancer metastasis”. The importance of CTCs in modern cancer research began in the mid 1990's with the demonstration that CTCs exist early in the course of the disease. Most of the tumor cells shed off into the circulation system have short lifespan and only a handful of highly active with high metastatic potential tumors cells survive in the circulation system to eventually aggregate forming clusters, hence tumor micro-thrombi. Thus, the detection of CTCs in the peripheral blood system would be an indication of possible occurrence of metastasis. CTCs have emerged as a reliable source of tumor cells while their concentration was found to have prognostic implications. CTC capture offers real-time access to cancer tissue without the need of an invasive biopsy, while their phenotypic and molecular interrogation can provide insight into the biological changes of the tumor that occur during treatment[22,23].

***CTC detection and GC***

The CTC detection process mainly includes separation, enrichment and identification, and since CTC in the peripheral blood of lower density, CTCs and blood cells should first be separated and enriched in order to improve the efficiency of the detection mechanism. There are mainly two kinds of separation methods: The first method comprises of separating the CTCs according to the morphological differences existing between the tumor and blood cell structure and conducting relevant immunohistochemistry or immunofluorescence analysis. However, this method lacks specificity and is prone to false positives. Hence, the second method, comprising of separation using immunological analysis, is more favorable.

Most tumors of epithelial origin express the epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK) antigen, while cells sourcing from bone marrow cells in the blood express molecules such as CD45 molecule[24]. The CELLSEARCH® Circulating Tumor Cell Kit, a product of Johnson (Veridex), is currently the world's first and only FDA approved CTC detection kit intended for the enumeration of CTC of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) in whole blood. This method is based on the use of iron nano-particles coated with a polymer layer carrying biotin analogues and conjugated with antibodies anti EpCAM for capturing CTCs. CTCs are hereby defined as cells tested as CK-PE+, DAPI+ and CD45-[25,26]. Clinical researches have already proven than the CTC count can effectively predict prognosis, progression free survival (PFS) and overall survival (OS) for breast, prostate and colorectal cancers with good specificity (99.7%) and high repetition rate (99.4%)[27].Previous research work have also stated that the CTC count is as good as a diagnostic indicator as imageological indexes, furthermore emphasizing that the CTC count can predict cancers at an early stage[28].

Nevertheless, in addition to the CTC count, recent researchers have shown interest in the molecular changes occurring in CTCs: Cui *et al*[29] found out that *piR-651* and *piR-823* are significantly lower in the peripheral blood of GC patients when compared to normal control; Zhou *et al*[30] found that the miR-421 level in the CTC obtained from peripheral blood of GC patients was significantly higher than that of their control group and their further investigation discovered that the transfection of *miR-421* inhibitors could significantly inhibit tumor growth in vivo. Zhang *et al*[31] analyzed the miRNA expression profile in 65 GC patients, 29 patients with recurrence and 36 patients without recurrence: the results indicated that the combination of *miR-375* and *miR-142-5p* could predict recurrence risk for GC patients. Furthermore, frequently recurring high levels of *miR-335* and poor overall survival correlated significantly with high levels of individual miRNAs in patients with GC[32]. Although previous studies suggested the use of numerous potential miRNAs as biomarkers in the diagnosis and prognosis of GC, the values of these miRNAs as biomarkers need to be further confirmed in human GC patients[33]. The changes at the level of miRNA in GC CTCs can prove to be ground-breaking and pivotal for GC research but the technology and expertise required manipulating and fully observing the behavior of miRNA are still crude and for future clinical use, this asset should be further developed and adapted for more clinical availability.

The molecular changes happening in CTCs obtained from the peripheral blood of GC patients have grasped the attention of more and more researchers recently; Cao *et al*[34] studied the expression of *Survivin* in the peripheral blood CTC of 98 GC patients and stated that just like the conventional pathological biomarkers, *Survivin mRNA* was an independent prediction factor for disease free survival and that a high *Survivin mRNA* expression after radical tumor resection was an indicator of tumor recurrence. Arigami *et al*[35] used quantitative RT-PCR for the evaluation of *B7-H3 mRNA* expression in 4 GC cell lines, 95 GC cases and 21 cases of healthy human peripheral blood: the results of the investigation confirmed that *B7-H3 mRNA* was expressed in all 4 GC cell lines while its expression in the peripheral blood of the GC patients was significantly higher than the healthy control group. They further discovered that the 5-year survival rate of GC patients with high *B7-H3* expression was significantly lower than the ones with low expression. Other researchers[36,37] collected blood samples from 53 preoperative GC cases and 20 healthy volunteers and investigated the expressions of *miR-21, miR-106a and miR-17* using RT-PCR: the results showed that the microRNA levels in the GC patients were significantly higher than the control group and the level of microRNA was related to the TNM staging, tumor size and histological classification[38]. Wang *et al*[39] used RT-PCR to monitor the mRNA expression of *MAGE-1* and *MAGE-3* in tumor cells and peripheral blood of GC patients: their results showed that among the 40 patients, the positive rates of *MAGE-1* and *MAGE-3 mRNA* were respectively 47.5% and 25% in the peripheral blood samples and 62.5% and 30% in the tumor tissue samples. They furthermore discovered that when *MAGE mRNA* was not expressed in the tumor tissues, it was also negative in the peripheral blood while the control comprising of 20 healthy subjects tested negative for *MAGE mRNA* expression, suggesting that *MAGE* could be a specific tumor marker in the detection of CTCs.

Nevertheless, the method of collection of CTCs markers such as CELLSEARCH also have their shortcomings, that is these methods are unable to capture and analyze cells lacking tumor marker expression, cells with low differentiation or tumor stem cells or EMT related cells in the blood. Therefore, there are other CTCs acquisition methods such as the ISET method (Isolation by Size of Epithelial Tumor cells) where the tumor cells are isolated and individually filtrated from the blood cells as a result of the different sizes[40] or the CanPatrol technique based on the nano-filtration of RNA in situ hybridization, methods which have been actively contributing to the research of serological diagnosis technology for GC, hence providing a new direction for development.

***ctDNA and circulating cell-free DNA***

Circulating cell-free DNA (cfDNA) is defined as extracellular DNA occurring in blood. cfDNA can be detected in the plasma or serum samples of not only patients suffering from cancer or other destructive diseases but also in healthy individuals. The tumor cells in the CTC and metastatic legions release circulating ctDNA in the peripheral blood after necrosis and apoptosis. In tumor patients, the ctDNA forms only part of cfDNA, other non-tumor cells also release cfDNA in the peripheral blood after necrosis and apoptosis. Previous research found out that the level ctDNA in the circulation of tumor patients is usually higher than that of healthy individuals and that cfDNA displayed the same biological characteristics as tumor tissues, suggesting that the cfDNA in tumor patients mostly comes from ctDNA while healthy human cfDNA is mostly derived from blood cells.

The similar and specific alterations found in DNA from both the tumor tissue and cfDNA proved the tumoral origin of the cfDNA in cancer patients. These tumor-specific changes of cfDNA included changes in molecular size, oncogene and tumor suppressor gene mutations, microsatellite alterations and hyper-methylation of several genes. The detection of these characteristic alterations in the background of “normal” cfDNA molecules in principle offers a higher diagnostic specificity in comparison with only quantitative measurements of total cfDNA alone. Qualitative and quantitative analysis of circulating cfDNA is an emerging non-invasive blood biomarker utilized to assess tumor progression and to evaluate prognosis, diagnosis and response to treatment. However, detection methods with high analytical sensitivity are an essential precondition for detecting these specific alterations because the proportion of cfDNA in tumor-specific alterations could be very small and varied[41].

***ctDNA/cfDNA and GC***

Recent literature has shown that there is certain concentration of cfDNA in the plasma of healthy persons, mostly released during blood cells apoptosis. Nevertheless, it has also been reported that in patients with advanced cancer, the cfDNA released during the necrosis or apoptosis of the tumor cells and tumor adjacent tissues can cause a significant increase in the plasma cfDNA level[42]. In a study conducted by Diehl *et al*[43], it was found out that per 100g tumor of colorectal cancer, 3.3% of the tumor DNA was shed into the circulatory system on a daily basis. Therefore, the determination of cfDNA in the peripheral blood of cancer patients can be used as a potential tumor marker.

Huang *et al*[44], Frattini *et al*[45] and Sozzi *et al*[46] respectively monitored the cfDNA levels in breast, colon and lung cancers: their results showed that the level of cfDNA significantly decreased after surgery and therefore, a decrease in the cfDNA level after surgery would imply positive outcome of the surgery and postoperative treatment while an increase in the cfDNA level would indicate poor outcome or signs of disease progression such as metastasis. Therefore, cfDNA may be used as an efficient marker in the monitor, prediction and evaluation of tumor therapy. However, the value of cfDNA in early diagnosis of cancer seems to be limited and the main reason is the lack of highly sensitive, reliable and specific methods of cfDNA extraction and quantitation.

At present, there has been some small sample studies on the status of cfDNA on the different outcomes of GC: Kim *et al*[47] studied the plasma cfDNA levels of 30 GC patients and 34 healthy controls, where the GC patients samples were retrieved before surgery and 24 hours after surgery; the results showed that the average levels of cfDNA in the healthy control group, patients with early GC, and with advanced GC were 79.78 ± 8.12 ng/mL, 106.88 ± 12.40 ng/mL, and 120.23 ± 10.08 ng/mL, respectively while the levels of cfDNA in the 24-hour-after-surgery group decreased significantly compared to the levels of cfDNA in the preoperation group. In another study, Park *et al*[48] found out that in their 54 GC patients and the 59 age-matched healthy controls, the mean levels of plasma cfDNA were 2.4-fold higher in the patient group compared with the control group, indicating that plasma cfDNA levels may be useful for predicting patients with GC.

ctDNA, as an emerging candidate biomarker for malignancies, has also been throroughly tackled over the last few years. Hawakawa *et al*[49] investigated the possible application of ctDNA in the monitoring of disease status of GC by performing targeted deep sequencing of plasma cell-free DNA by massively parallel sequencing in patients with tumors harboring TP53 mutations and they found out that 3/10 patients with TP53 mutations in primary tumors showed detectable TP53 mutation levels in preoperative cfDNA to conclude that ctDNA could serve as a useful biomarker to monitor GC progression and residual disease.

Hence, in light of the research results, it is clear that the changes in the levels of cfDNA/ctDNA can prove to be reliable biomarkers in the detection early stages of GC and as a valuable tool for monitoring, estimating and evaluation curative resection, therapeutic effect of preoperative and postoperative treatment and disease prognosis.

***cfDNA methylation and GC***

The methylation of tumor suppressor gene promoter is an important mechanism for the inactivation of tumor suppressor gene and this mechanism plays a very important role in the occurrence and progression of a variety of tumors. The abnormal gene methylation has already been detected in the plasma of head and neck, nasopharyngeal, breast, esophageal, gastric and colorectal cancer patients. P14 belongs to INK4a/ARP of the tumor suppressor gene and during the investigation of the GC cell line[41,50], 5 out of 7 cell lines were found to lack the corresponding gene mRNA whereby further analysis discovered that the methylation of the gene promoter was an important regulation mechanism for the silencing of the p14 gene in GC. Analysis of GC specimen found that the rate of methylation of the p14 promoter in invasive GC was 45.5%[51].

On the other hand, p15, as a CDKIs inhibitor, is also a tumor suppressor gene. The deletion or mutation of p15 is rare in GC, but the methylation of CpG region promotes the abnormal transcription of mRNA, leading to the inactivation of p15, causing GC. A study conducted by Leung *et al*[52] found out that methylation of the p15 promoter was present in the tumor tissues of 68% of GC patients and in the plasma of 81% of the GC patients. In the plasma of the GC patients, the detection rate of abnormal methylation of O6-methylgua-nine DNA methyltransferase (MGMT), p15 and mismatch repair gene 1 was 59%, 40% and 41% respectively while in the plasma of healthy control, the detection rate of the abnormal methylation of the corresponding genes was only 34%, 13% and 8%.

Kolesnikova *et al*[53] and Tani *et al*[54] used the methylation specific polymerase chain reaction (MSP) method to detect the methylation status of MGMT, p15, and Hm-LH1 with a normal control of 22 healthy volunteers: the results showed that the detection rate of MGMT, p15 and Hm-LH1 methylation in the plasma of 20 GC patients was 50%, 70% and 25% respectively, while the methylation detection rate in GC patients with stages III, IV and distant metastasis GC was 90%, 90% and 60% respectively. No abnormal corresponding methylation was detected in the healthy controls.

Leung *et al*[55,56] used methylation-specific PCR to investigate the methylation status of p15 and p16 in GC cell lines and tumor tissues of 26 GC cases: p15 methylation disorder was detected in 4 of the GC cell lines, p16 methylation disorder was detected in 3 of the cell lines while in the 26 GC cases, there was a prevalence of 73.1% for p15 hyper-methylation and 64.5% for pl6 hyper-methylation. This result implicated that the inactivation of the multiple tumor suppressor gene p15 and p16 genes was associated with the occurrence of GC.

The Down-regulation of mRNA expression is caused by DNA methylation disorder. It is considered that DNA methylation plays a role in the inactivation of p16 gene. Shim *et al*[57] used MSP to investigate the level of p16 in GC and they found out that 42% of the GC patients had hyper-methylation and among the 22 positive cases, 19 cases had complete p16 immuno-activity deactivation while only 2 cases were tested negative for methylation. The correlation of the immune-activity and hyper-methylation of p16 shows that methylation is an important mechanism for the deactivation of p16 in GC. Song *et al*[58] carried out an analysis of 9 GC cell lines and found out that the inactivation of p16 expression was accompanied by the hyper-methylation of the promoter: in 28 of the GC patients, 6 cases presented with the absence of p16 expression while in hyper-methylation of the promoter region was noted in 5 cases. In vitro studies suggest that 22% of GC patients did not express the p16 protein due to the methylation of the p16 while there was no methylation of the promoter of the latter gene in gastritis patients. 48% of GC and 59% of precancerous tissues presented with the p16 promoter methylation phenomenon, which indicated that the methylation of the promoter of this gene starts in the early stages of GC and its frequency was relatively high, further classifying it as a potential biomarker for the prediction of GC[59-62].

Sakakura *et al*[63] investigated the pre-operative and post-operative Runt related transcription factor 3 (Runx3) gene methylation level in 65 GC cases and found out that Runx3 methylation was detected in the pre-operative serum of 29% (19/65) GC patients and that the Runx3 methylation index was related to the tumor grade, tissue type, lymphatic invasion and metastasis and its sensitivity was higher than CEA. On the other hand, the Runx3 methylation level in post-operative serum significantly. Therefore, it can be seen that the detection of abnormal methylation of DNA can also be used as a tumor marker for cfDNA.

Other research work pertaining to the APC gene in GC[64] revealed no APC genes mutations while using MSP to analyze GC sample and GC cell lines found out that 82.5% of primary GC, GC adjacent mucosa of 97.5% of the patients and 10 GC cell lines had high APC 1A promoter methylation while the 1B promoter had not undergone methylation[65-69]. Due to methylation, in 10 GC cell lines, the 1A exon did not express APC while the IB exon expressed APC, suggesting that the 1A APC promoter methylation could be used as a biomarker for early stage GC.

**Conclusion**

The tremendous advances in technology have allowed the development of several methods to understand the mechanisms underlying gastric carcinogenesis, resulting in the identification of a large number of molecular targets such as CTC, ctDNA, serum markers that can be used as biomarkers with diagnostic and prognostic potential. Several of these (especially HER-2 amplification, miR-19a/b, miR-160a and p16 hyper-methylation) can also be used for the early indication of carcinogenic activity, prediction of therapeutic response or prognosis. However, most of the biomarkers being unraveled over time tend to show very low sensitivity when tested on large population. Furthermore, many of these biomarkers, especially genetic markers such as miRNA, ctDNA and so on, have been tested in very restricted parameters since GC, as with other types of tumor, is highly influenced by ethnic and environmental factors, therefore making it even harder to find specific and unbiased markers for the disease. Therefore, the simplest approach at present is to validate the discovered markers in the target population and to use several biomarkers for each patient. The use of proteomic approach is very pragmatic whereby more emphasis is laid on protein expression, which is hereby very independent of the cause (genetic or epigenetic) of any altered pattern. However, there are some limitations to that approach, such as the availability of studies in only a few populations and the cost of the analysis, which remains very high.

There has been a lot of progress over the years in the mechanisms behind the correlation between methylation and GC, but so far there has been no concrete clinical use of the GC gene methylation in the early diagnosis and intervention of GC. Currently methylation of circulating DNA is detected in whole blood, but a higher positive rate could be achieved with the enrichment and separation of CTC. While investigating about possible biomarkers, various molecular features of GC have been unfolded, giving researchers more ground for research since the characteristics and molecular background of GC have been so vague and indistinctive.

Nevertheless, the detection and analysis of CTC and circulating GC cell DNA (ctDNA) and its methylation, have shown great promise for the early detection, evaluation of treatment efficacy and outcome in GC. The molecular changes in CTC and ctDNA could be the possible molecular targets as not only more sensitive and specific GC blood indicators, but also as targets for individualized treatment, hence opening up a new field for clinical application in oncology as Table 1. Hence, new and reliable proteomics techniques are encouraged in order to identify novel and unbiased serum biomarkers which not only would give us more perspective on the nature of GC, but would give us a better interface while dealing with GC patients.

With the development of technology, a large number of modern techniques of research can be applied in the serological diagnosis of tumor. Yet, the main important features to the serological diagnosis model should not only be high sensitivity and specificity, but must also bestow high maneuverability, reliability and repeatability. In order to investigate the feasibility of the new diagnostic technologies in the clinical diagnosis of tumors or GC, more clinical data needs to be processed to design a reasonable and repeatable validation model.

**References**

1 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015; **65**: 5-29 [PMID: 25559415 DOI: 10.3322/caac.21254]

2 **Ucar E**, Semerci E, Ustun H, Yetim T, Huzmeli C, Gullu M. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer. *Adv Ther* 2008; **25**: 1075-1084 [PMID: 18821070 DOI: 10.1007/s12325-008-0100-4]

3 **Liu W**, Yang Q, Liu B, Zhu Z. Serum proteomics for gastric cancer. *Clin Chim Acta* 2014; **431**: 179-184 [PMID: 24525212 DOI: 10.1016/j.cca.2014.02.001]

4 **Ishigami S**, Natsugoe S, Hokita S, Che X, Tokuda K, Nakajo A, Iwashige H, Tokushige M, Watanabe T, Takao S, Aikou T. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. *J Clin Gastroenterol* 2001; **32**: 41-44 [PMID: 11154168]

5 **Schwarzenbach H**, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. *Clin Cancer Res* 2009; **15**: 1032-1038 [PMID: 19188176 DOI: 10.1158/1078-0432.CCR-08-1910]

6 **Schwarzenbach H**, Chun FK, Lange I, Carpenter S, Gottberg M, Erbersdobler A, Friedrich MG, Huland H, Pantel K. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer. *Int J Cancer* 2007; **120**: 1465-1471 [PMID: 17205532]

7 **Heitzer E**, Auer M, Ulz P, Geigl JB, Speicher MR. Circulating tumor cells and DNA as liquid biopsies. *Genome Med* 2013; **5**: 73 [PMID: 23998943 DOI: 10.1186/gm477]

8 **Haber DA**, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. *Cancer Discov* 2014; **4**: 650-661 [PMID: 24801577 DOI: 10.1158/2159-8290.CD-13-1014]

9 **Scher HI**, Morris MJ, Larson S, Heller G. Validation and clinical utility of prostate cancer biomarkers. *Nat Rev Clin Oncol* 2013; **10**: 225-234 [PMID: 23459624 DOI: 10.1038/nrclinonc.2013.30]

10 **Cohen SJ**, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 3213-3221 [PMID: 18591556 DOI: 10.1200/JCO.2007]

11 **Pantel K**, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. *Trends Mol Med* 2010; **16**: 398-406 [PMID: 20667783 DOI: 10.1016/j.molmed.2010.07.001]

12 **Liu W**, Liu B, Cai Q, Li J, Chen X, Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. *Clin Chim Acta* 2012; **413**: 1098-1106 [PMID: 22446497 DOI: 10.1016/j.cca.2012.03.003]

13 **Uen YH**, Lin KY, Sun DP, Liao CC, Hsieh MS, Huang YK, Chen YW, Huang PH, Chen WJ, Tai CC, Lee KW, Chen YC, Lin CY. Comparative proteomics, network analysis and post-translational modification identification reveal differential profiles of plasma Con A-bound glycoprotein biomarkers in gastric cancer. *J Proteomics* 2013; **83**: 197-213 [PMID: 23541716 DOI: 10.1016/j.jprot.2013.03.007]

14 **Bones J**, Mittermayr S, O'Donoghue N, Guttman A, Rudd PM. Ultra performance liquid chromatographic profiling of serum N-glycans for fast and efficient identification of cancer associated alterations in glycosylation. *Anal Chem* 2010; **82**: 10208-10215 [PMID: 21073175 DOI: 10.1021/ac102860w]

15 **Bones J**, Byrne JC, O'Donoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. *J Proteome Res* 2011; **10**: 1246-1265 [PMID: 21142185 DOI: 10.1021/pr101036b]

16 **Klaamas K**, Kodar K, Kurtenkov O. An increased level of the Concanavalin A-positive IgG in the serum of patients with gastric cancer as evaluated by a lectin enzyme-linked immunosorbent assay (LELISA). *Neoplasma* 2008; **55**: 143-150 [PMID: 18237253]

17 **Xu Y**, Zhang L, Hu G. Potential application of alternatively glycosylated serum MUC1 and MUC5AC in gastric cancer diagnosis. *Biologicals* 2009; **37**: 18-25 [PMID: 18848467 DOI: 10.1016/j.biologicals.2008.08.002]

18 **Li K**, Sun Z, Zheng J, Lu Y, Bian Y, Ye M, Wang X, Nie Y, Zou H, Fan D. In-depth research of multidrug resistance related cell surface glycoproteome in gastric cancer. *J Proteomics* 2013; **82**: 130-140 [PMID: 23470797 DOI: 10.1016/j.jprot.2013.02.021]

19 **Li P**, Ma D, Zhu ST, Tang XD, Zhang ST. Serum peptide mapping in gastric precancerous lesion and cancer. *J Dig Dis* 2014; **15**: 239-245 [PMID: 24438315 DOI: 10.1111/1751-2980.12130]

20 **Lu HB**, Zhou JH, Ma YY, Lu HL, Tang YL, Zhang QY, Zhao CH. Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer. *Jpn J Clin Oncol* 2010; **40**: 336-342 [PMID: 20089528 DOI: 10.1093/jjco/hyp175]

21 **Gupta GP**, Massagué J. Cancer metastasis: building a framework. *Cell* 2006; **127**: 679-695 [PMID: 17110329 DOI: 10.1016/j.cell.2006.11.001]

22 **Huang X**, Gao P, Song Y, Sun J, Chen X, Zhao J, Xu H, Wang Z. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. *BMC Cancer* 2015; **15**: 202 [PMID: 25880692 DOI: 10.1186/s12885-015-1218-9]

23 **Galletti G**, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, Kirby BJ, Giannakakou P. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. *Lab Chip* 2014; **14**: 147-156 [PMID: 24202699 DOI: 10.1039/c3lc51039e]

24 **Sleijfer S**, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA. Circulating tumour cell detection on its way to routine diagnostic implementation? *Eur J Cancer* 2007; **43**: 2645-2650 [PMID: 17977713]

25 **Naoe M**, Ogawa Y, Morita J, Omori K, Takeshita K, Shichijyo T, Okumura T, Igarashi A, Yanaihara A, Iwamoto S, Fukagai T, Miyazaki A, Yoshida H. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. *Cancer* 2007; **109**: 1439-1445 [PMID: 17326057]

26 **Racila E**, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. Detection and characterization of carcinoma cells in the blood. *Proc Natl Acad Sci USA* 1998; **95**: 4589-4594 [PMID: 9539782]

27 **Dawson SJ**, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *N Engl J Med* 2013; **368**: 1199-1209 [PMID: 23484797 DOI: 10.1056/NEJMoa1213261]

28 **Punnoose EA**, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. *Clin Cancer Res* 2012; **18**: 2391-2401 [PMID: 22492982 DOI: 10.1158/1078-0432]

29 **Cui L**, Lou Y, Zhang X, Zhou H, Deng H, Song H, Yu X, Xiao B, Wang W, Guo J. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using piRNAs as markers. *Clin Biochem* 2011; **44**: 1050-1057 [PMID: 21704610 DOI: 10.1016/j.clinbiochem.2011.06.00]

30 **Zhou H**, Xiao B, Zhou F, Deng H, Zhang X, Lou Y, Gong Z, Du C, Guo J. MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. *Biomarkers* 2012; **17**: 104-110 [PMID: 22263628 DOI: 10.3109/1354750X.2011.614961]

31 **Zhang X**, Yan Z, Zhang J, Gong L, Li W, Cui J, Liu Y, Gao Z, Li J, Shen L, Lu Y. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. *Ann Oncol* 2011; **22**: 2257-2266 [PMID: 21343377 DOI: 10.1093/annonc/mdq758]

32 **Yan Z**, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, Chen F, Zheng G. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. *PLoS One* 2012; **7**: e40037 [PMID: 22802949 DOI: 10.1371/journal.pone.0040037]

33 **Zhu X**, Lv M, Wang H, Guan W. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. *Dig Dis Sci* 2014; **59**: 911-919 [PMID: 24337687 DOI: 10.1007/s10620-013-2970-9]

34 **Cao W**, Yang W, Li H, Lou G, Jiang J, Geng M, Xi W, Ren R, Qu Q, Jin X, Zhu Y, Jin Y. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. *J Surg Oncol* 2011; **103**: 110-115 [PMID: 21259243 DOI: 10.1002/jso.21777]

35 **Arigami T**, Uenosono Y, Hirata M, Yanagita S, Ishigami S, Natsugoe S. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. *Cancer Sci* 2011; **102**: 1019-1024 [PMID: 21251161 DOI: 10.1111/j.1349-7006.2011.01877.x]

36 **Zheng Y**, Cui L, Sun W, Zhou H, Yuan X, Huo M, Chen J, Lou Y, Guo J. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. *Cancer Biomark* 2011-2012; **10**: 71-77 [PMID: 22430134 DOI: 10.3233/CBM-2011-0231]

37 **Zhou H**, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, Cheng J, Xiao BX. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. *J Mol Med* (Berl) 2010; **88**: 709-717 [PMID: 20349219 DOI: 10.1007/s00109-010-0617-2]

38 **Zhu A**, Xia J, Zuo J, Jin S, Zhou H, Yao L, Huang H, Han Z. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. *Med Oncol* 2012; **29**: 2701-2709 [PMID: 22167392 DOI: 10.1007/s12032-011-0134-3]

39 **Wang WX**, Li YB, Xie XL, Shu XL, Ouyang XH. [Detection of tumor cells in peripheral blood of patients with gastric cancer using mRNA of MAGE genes as markers]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2009; **12**: 611-614 [PMID: 19921576]

40 **Farace F**, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. *Br J Cancer* 2011; **105**: 847-853 [PMID: 21829190 DOI: 10.1038/bjc.2011.294]

41 **Philipp AB**, Nagel D, Stieber P, Lamerz R, Thalhammer I, Herbst A, Kolligs FT. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. *BMC Cancer* 2014; **14**: 245 [PMID: 24708595 DOI: 10.1186/1471-2407-14-245]

42 **Stroun M**, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, Rossier A, Chen XQ, Anker P. The origin and mechanism of circulating DNA. *Ann N Y Acad Sci* 2000; **906**: 161-168 [PMID: 10818614]

43 **Diehl F**, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B. Detection and quantification of mutations in the plasma of patients with colorectal tumors. *Proc Natl Acad Sci USA* 2005; **102**: 16368-16373 [PMID: 16258065]

44 **Huang ZH**, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. *Cancer Lett* 2006; **243**: 64-70 [PMID: 16412565]

45 **Frattini M**, Gallino G, Signoroni S, Balestra D, Lusa L, Battaglia L, Sozzi G, Bertario L, Leo E, Pilotti S, Pierotti MA. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. *Cancer Lett* 2008; **263**: 170-181 [PMID: 18395974 DOI: 10.1016/j.canlet.2008.03.021]

46 **Sozzi G**, Conte D, Mariani L, Lo Vullo S, Roz L, Lombardo C, Pierotti MA, Tavecchio L. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. *Cancer Res* 2001; **61**: 4675-4678 [PMID: 11406535]

47 **Kim K**, Shin DG, Park MK, Baik SH, Kim TH, Kim S, Lee S. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. *Ann Surg Treat Res* 2014; **86**: 136-142 [PMID: 24761422 DOI: 10.4174/astr.2014.86.3.136]

48 **Park JL**, Kim HJ, Choi BY, Lee HC, Jang HR, Song KS, Noh SM, Kim SY, Han DS, Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. *Oncol Lett* 2012; **3**: 921-926 [PMID: 22741019]

49 **Hamakawa T**, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, Mori M, Doki Y, Kato K. Monitoring gastric cancer progression with circulating tumour DNA. *Br J Cancer* 2015; **112**: 352-356 [PMID: 25490524 DOI: 10.1038/bjc.2014.609]

50 **Ahn JB**, Rha SY, Shin SJ, Jeung HC, Kim TS, Zhang X, Park KH, Noh SH, Roh JK, Chung HC. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. *Cancer Lett* 2010; **288**: 124-132 [PMID: 19619937 DOI: 10.1016/j.canlet.2009.06.031]

51 **Esteller M**, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. *Cancer Res* 2001; **61**: 2816-2821 [PMID: 11306450]

52 **Leung WK**, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. *Br J Cancer* 2005; **92**: 2190-2194 [PMID: 15942635]

53 **Kolesnikova EV**, Tamkovich SN, Bryzgunova OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov PP, Rykova EY. Circulating DNA in the blood of gastric cancer patients. *Ann N Y Acad Sci* 2008; **1137**: 226-231 [PMID: 18837952 DOI: 10.1196/annals.1448.009]

54 **Tani N**, Ichikawa D, Ikoma D, Ikoma H, Sai S, Tomita H, Okamoto K, Kikuchi S, Fujiwara H, Ochiai T, Ueda Y, Otsuji E, Hagiwara A, Yamagishi H. [An early detection of recurrence using reverse transcriptase-polymerase chain reaction (RT-PCR) and methylation-specific polymerase chain reaction (MSP) from peripheral blood in patients after gastrectomy]. *Gan To Kagaku Ryoho* 2006; **33**: 1720-1722 [PMID: 17212086]

55 **Leung WK**, Yu J, Ng EK, To KF, Ma PK, Lee TL, Go MY, Chung SC, Sung JJ. Concurrent hypermethylation of multiple tumor-related genes in gastric carcinoma and adjacent normal tissues. *Cancer* 2001; **91**: 2294-2301 [PMID: 11413518]

56 **Leung WK**, To KF, Man EP, Chan MW, Bai AH, Hui AJ, Chan FK, Sung JJ. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. *Am J Gastroenterol* 2005; **100**: 2274-2279 [PMID: 16181380]

57 **Shim YH**, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. *Lab Invest* 2000; **80**: 689-695 [PMID: 10830779]

58 **Song SH**, Jong HS, Choi HH, Kang SH, Ryu MH, Kim NK, Kim WH, Bang YJ. Methylation of specific CpG sites in the promoter region could significantly down-regulate p16(INK4a) expression in gastric adenocarcinoma. *Int J Cancer* 2000; **87**: 236-240 [PMID: 10861481]

59 **Esteller M**. Aberrant DNA methylation as a cancer-inducing mechanism. *Annu Rev Pharmacol Toxicol* 2005; **45**: 629-656 [PMID: 15822191]

60 **Lee TL**, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. *Clin Cancer Res* 2002; **8**: 1761-1766 [PMID: 12060614]

61 **Chan AW**, Chan MW, Lee TL, Ng EK, Leung WK, Lau JY, Tong JH, Chan FK, To KF. Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. *Oncol Rep* 2005; **13**: 937-941 [PMID: 15809761]

62 **Yu J**, Leung WK, Lee TL, Tse PC, To KF, Sung JJ. Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma. *Int J Oncol* 2003; **22**: 1025-1031 [PMID: 12684668]

63 **Sakakura C**, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. *Anticancer Res* 2009; **29**: 2619-2625 [PMID: 19596937]

64 **Kang GH**, Lee S, Kim WH, Lee HW, Kim JC, Rhyu MG, Ro JY. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. *Am J Pathol* 2002; **160**: 787-794 [PMID: 11891177]

65 **Tsuchiya T**, Tamura G, Sato K, Endoh Y, Sakata K, Jin Z, Motoyama T, Usuba O, Kimura W, Nishizuka S, Wilson KT, James SP, Yin J, Fleisher AS, Zou T, Silverberg SG, Kong D, Meltzer SJ. Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. *Oncogene* 2000; **19**: 3642-3646 [PMID: 10951570]

66 **Hong B**, Zu Y. Detecting circulating tumor cells: current challenges and new trends. *Theranostics* 2013; **3**: 377-394 [PMID: 23781285 DOI: 10.7150/thno.5195]

67 **Forshew T**, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J, May AP, Caldas C, Brenton JD, Rosenfeld N. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. *Sci Transl Med* 2012; **4**: 136ra68 [PMID: 22649089 DOI: 10.1126/scitranslmed.3003726]

68 **Murtaza M**, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. *Nature* 2013; **497**: 108-112 [PMID: 23563269 DOI: 10.1038/nature12065]

69 **Leary RJ**, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, Antipova A, Lee C, McKernan K, De La Vega FM, Kinzler KW, Vogelstein B, Diaz LA, Velculescu VE. Development of personalized tumor biomarkers using massively parallel sequencing. *Sci Transl Med* 2010; **2**: 20ra14 [PMID: 20371490 DOI: 10.1126/scitranslmed.3000702]

**P-Reviewer:** Jayavelu ND, Park ws **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Novel biomarkers in the breakthrough of gastric cancer diagnosis**

|  |  |  |
| --- | --- | --- |
| **Biomarkers/proteomics techniques** | **Methods and Investigation** | **Ref.** |
| **MALDI-TOF-MS** | Spectral peaks for the peptides with (m/z) values of 1741 and 4210 were the most significantly different between precancerous lesions, GC patients and healthy controls and the sensitivity and specificity of this diagnostic model was found to be clinically significant. | Li *et al*[19]  |
| **SELDI** | Compared to conventional biomarkers CEA, in a micro-particle enzyme immunoassay, 5 distinct protein peaks at 2046, 3179, 1817, 1725 and 1929 m/z were automatically chosen as components of the best biomarker pattern for diagnosis of GC, with a single protein peak at 4665 m/z, which could distinguish between stage I/II and stage III/IV gastric cancer with high specificity and sensitivity  | Lu *et al*[20]  |
| **CTCs** | Clinical researches have already proven than the CTC count can effectively predict prognosis, progression free survival (PFS) and overall survival (OS) for breast, prostate and colorectal cancers with good specificity and high repetition rate.  | Dawson *et al*[27] |
| **piR-651 and piR-823** | piR-651 and piR-823 are significantly lower in the peripheral blood of gastric cancer patients when compared to normal control | Cui *et al*[29] |
| **miR-421** | miR-421 level in CTC obtained from peripheral blood of GC patients was significantly higher than that of their control group and the transfection of miR-421 inhibitors could significantly inhibit tumor growth in vivo.  | Zhou *et al*[30]  |
| **miR-375 and miR-142-5p** | miRNA expression profile in gastric cancer patients indicated that the combination of miR-375 and miR-142-5p could predict recurrence risk for gastric cancer patients | Zhang *et al*[31]  |
| **Survivin mRNA** | Survivin mRNA is an independent prediction factor for disease free survival, whereby a high Survivin mRNA expression after radical tumor resection was an indicator of tumor recurrence | Cao *et al*[34]  |
| **B7-H3 mRNA** | Quantitative RT-PCR confirmed that B7-H3 mRNA was expressed in all 4 GC cell lines and that the 5-year survival rate of GC patients with high B7-H3 expression was significantly lower than the ones with low expression | Arigami *et al*[35]  |
| **miR-21, miR-106a and miR-17** | miR-21, miR-106a and miR-17 expression patterns showed that the microRNA levels in the GC patients were significantly higher than the control group and the level of microRNA was related to the TNM staging, tumor size and histological classification[38] | Zheng *et al*[36] |
| **MAGE mRNA** |  MAGE-1 and MAGE-3 mRNA is expressed in tumor cells and peripheral blood of GC patients while they are not expressed in the healthy controls; suggesting that MAGE could be a specific tumor marker in the detection of CTCs.  | Wang *et al*[39]  |
| **cfDNA** | cfDNA significantly decreased after surgery and therefore, a decrease in the cfDNA level after surgery would imply positive outcome of the surgery and postoperative treatment while an increase in the cfDNA level would indicate poor outcome or signs of disease progression such as metastasis | Huang *et al*[44], Frattini *et al*[45] and Sozzi *et al*[46]  |
| **cfDNA** | As compared to GC patients and advanced GC patients, the level of cfDNA in normal subjects was lower; whereby the level of cfDNA in the 24-hour-after-surgery group decreased significantly compared to the pre-operation group.  | Kim *et al*[47]  |
| **cfDNA** | The mean level of plasma cfDNA in GC was 2.4-fold higher in the patient group compared with the control group, indicating that plasma cfDNA levels may be useful for predicting patients with gastric cancer | Park *et al*[48] |
| **TP53 mutations** | Targeted deep sequencing of plasma cell-free DNA by massively parallel sequencing was performed in patients with tumors harboring TP53 mutations and found detectable TP53 mutation levels in preoperative cfDNA to conclude that ctDNA could serve as a useful biomarker to monitor gastric cancer progression and residual disease. | Hawakawa *et al*[49]  |
| **p14 promoter methylation** | Analysis of GC specimen found that the rate of methylation of the p14 promoter in invasive GC was 45.5%  | Leung *et al*[54]  |
| **p15 promoter methylation** | Methylation of the p15 promoter was present in GC patients whereby there was a higher detection rate of abnormal methylation of O6-methylgua-nine DNA methyltransferase (MGMT), p15 and mismatch repair gene as compared to healthy controls. | Leung *et al*[54]  |
| **MGMT, p15, and Hm-LH1 Methylation** | The methylation specific polymerase chain reaction (MSP) method was used to detect the methylation status of MGMT, p15, and Hm-LH1 and found that there was a high detection rate of MGMT, p15 and Hm-LH1 methylation in the plasma of GC, with an even higher methylation detection rate in stages III, IV and distant metastasis GC while there was no abnormal corresponding methylation in the healthy controls. | Kolesnikova *et al*[55]Tani et al[56]  |
| **p15 and p16 Methylation** | methylation-specific PCR was used to investigate the methylation status of p15 and p16 in GC cell lines and tumor tissues and the findings implicated that the inactivation of the multiple tumor suppressor gene p15 and p16 genes was associated with the occurrence of GC | Leung *et al*[57,58]  |
| **p16 hyper-methylation** | MSP was used to investigate the level of p16 in GC and they found out that the correlation of the immune-activity and hyper-methylation of p16 shows that methylation is an important mechanism for the deactivation of p16 in GC and that the inactivation of p16 expression was accompanied by the hyper-methylation of the promoter. | Shim *et al*[59] Song *et* al[60]  |
| **Runt related transcription factor 3 (Runx3) gene methylation** | The pre-operative and post-operative Runt related transcription factor 3 (Runx3) gene methylation level and the results showed that the Runx3 methylation index was related to the tumor grade, tissue type, lymphatic invasion and metastasis and its sensitivity was higher than CEA. On the other hand, the Runx3 methylation level in post-operative serum significantly.  | Sakakura *et al*[65]  |

MALDI-TOF-MS: matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; SELDI: Surface-enhanced Laser Desorption Ionization; CTCs: circulating tumor cells; cfDNA: cell free DNA; ctDNA: cell tumor DNA; MGMT: O6-methylgua-nine DNA methyltransferase.